# A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

Source: https://onco.cc/trials/nct05487170/  
OnCo record `nct05487170` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of RNK05047 in advanced solid tumours, run by Ranok Therapeutics (Hangzhou) Co., Ltd., now recruiting.

## Summary

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) is a phase 1/2 interventional study registered as NCT05487170 by Ranok Therapeutics (Hangzhou) Co., Ltd., with 32 participants planned, started 2022-07-12 and due to reach its primary completion in 2025-06-01. Interventions recorded: RNK05047.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05487170
- Phase: 1/2
- Setting: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Chaperone-mediated Protein Degrader RNK05047 in Subjects With Advanced Solid Tumors (CHAMP-1)
- Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd.
- Enrolled: 32

## Sources

- ClinicalTrials.gov NCT05487170: https://clinicaltrials.gov/study/NCT05487170

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [RNK05047](https://onco.cc/drugs/rnk05047/)

---
JSON: https://onco.cc/api/v1/entities/nct05487170.json